Methylphenidatehydrochlorid Stada Arzneimittel Ag

Methylphenidate Hydrochloride, the active ingredient in Methylphenidatehydrochlorid Stada Arzneimittel Ag, is a central nervous system stimulant presented as an oral formulation for oral use. It is prescribed for attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidatehydrochlorid Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride acts on central nervous system pathways to improve attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): enhances focus, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and improves alertness.

Methylphenidate Hydrochloride may cause a range of adverse reactions. Patients should be monitored for any new or worsening symptoms.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Abdominal pain: stomach discomfort or cramps. - Increased heart rate: tachycardia or palpitations. - Anxiety: heightened nervousness or restlessness.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or chest pain. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Growth suppression: reduced height velocity in children. - Motor or vocal tics: involuntary movements or sounds. - Priapism: prolonged, painful erection.

Before initiating therapy with Methylphenidate Hydrochloride, clinicians should evaluate patient history and monitor for potential risks.

- Cardiovascular assessment: check blood pressure and heart rate. - Psychiatric evaluation: screen for history of psychosis or bipolar disorder. - Growth monitoring: track height and weight in pediatric patients. - Substance abuse history: assess for potential misuse or dependence. - Drug interaction review: consider concomitant medications that may affect catecholamine levels. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Methylphenidate Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Antihypertensive agents: may diminish blood‑pressure‑lowering effect. - CYP2D6 inhibitors: increase methylphenidate plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Alcohol: may enhance central nervous system stimulation. - SSRIs or other antidepressants: potential for serotonin syndrome. - Antacids: may alter gastrointestinal absorption of the drug.